Rare Lymphomas

  • Martin Dreyling
  • Michael E. Williams

Part of the Hematologic Malignancies book series (HEMATOLOGIC)

Table of contents

  1. Front Matter
    Pages i-x
  2. General

    1. Front Matter
      Pages 1-1
    2. German Ott, Eric D. Hsi, Jan Delabie, Scott Rodig
      Pages 3-16
    3. Gordana Raca, Jo-Anne van der Krogt, Michelle M. Le Beau, Iwona Wlodarska
      Pages 17-60
    4. Sören-Sebastian Wenzel, Georg Lenz
      Pages 61-69
    5. Andrew Lipsky, Patricia Pérez-Galán, Claudio Agostinelli, Pier Paolo Piccaluga, Stefano A. Pileri, Adrian Wiestner
      Pages 71-95
  3. Disease-Specific: T-NHL

    1. Front Matter
      Pages 97-97
    2. Kunihiro Tsukasaki, Kensei Tobinai
      Pages 99-110
    3. Anas Younes, Pier Luigi Zinzani, Scott Rodig, Jan Delabie
      Pages 111-120
    4. Won Seog Kim, Seok Jin Kim, Young Hyeh Ko
      Pages 121-131
    5. Jasmine Zain, Michael Weichenthal, Scott Rodig, Jan Delabie
      Pages 133-167
  4. Disease-Specific: B-NHL

    1. Front Matter
      Pages 169-169
    2. Nicola Gökbuget, Paul Barr, Jonathan W. Friedberg, Eric D. Hsi, German Ott
      Pages 171-194
    3. Peter Johnson, Jan Delabie, Scott Rodig, Maurizio Martelli
      Pages 195-206
    4. Agnieszka Korfel, James Rubenstein, German Ott, Eric D. Hsi
      Pages 207-223
    5. Kieron Dunleavy, German Ott, Eric D. Hsi, Michele Spina
      Pages 225-240
    6. Catherine Thieblemont, Steven Bernstein, Scott Rodig, Jan Delabie
      Pages 241-251
    7. Caron A. Jacobson, Luca Arcaini, Ann S. LaCasce, Jan Delabie, Scott Rodig
      Pages 253-276
    8. Michael E. Williams, L. Kyle Brett, Martin Dreyling, German Ott, Eric D. Hsi
      Pages 277-302
    9. Véronique Leblond, Giampaolo Merlini, Steven P. Treon, Scott Rodig, Jan Delabie
      Pages 303-329

About this book

Introduction

The past decade has witnessed tremendous progress in the diagnostic and therapeutic approaches to malignant lymphoma as well as in understanding of the underlying molecular pathogenesis. Optimal treatment strategies are now based not only on accurate diagnosis but also on thorough evaluation of clinical and molecular risk factors. Even more importantly, molecular targeted approaches have been shown to be effective in the treatment of distinct lymphoma subtypes. Against this background, clinical management of especially the rare lymphomas remains a challenge for the general oncologist.

 

This book provides a comprehensive overview of current treatment strategies in these rare lymphoma subtypes. Experts in the field from around the world describe the histomorphology in a clinically relevant manner, consider the role of risk factors in detail, and discuss the spectrum of therapeutic approaches. Special emphasis is placed on the translation of molecular science into clinical care, and a disease-specific algorithm is proposed for each entity. This book will prove an excellent resource for both experienced and inexperienced practitioners.

Keywords

Malignant Lymphoma Molecular Pathogenesis Targeted Approaches

Editors and affiliations

  • Martin Dreyling
    • 1
  • Michael E. Williams
    • 2
  1. 1.Medizinischen Klinik und Poliklinik IIIUniversität München Klinikum GroßhadernMünchenGermany
  2. 2.Division of Hematology/Oncology and Cancer CenterUniversity of Virginia Health SystemCharlottesvilleUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-642-39590-1
  • Copyright Information Springer-Verlag Berlin Heidelberg 2014
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Medicine
  • Print ISBN 978-3-642-39589-5
  • Online ISBN 978-3-642-39590-1
  • About this book